- Home
- DBD vs BCRX Comparison
DBD vs BCRX Comparison
Compare DBD & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DBD | BCRX |
|---|---|---|
| Founded | 1859 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.6B |
| IPO Year | N/A | 1994 |
Fundamental Metrics
Financial Performance| Metric | DBD | BCRX |
|---|---|---|
| Price | $68.12 | $7.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $76.67 | $20.08 |
| AVG Volume (30 Days) | 232.0K | ★ 3.8M |
| Earning Date | 02-11-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43573.14 | N/A |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $3,690,400,000.00 | $599,816,000.00 |
| Revenue This Year | $2.72 | $39.98 |
| Revenue Next Year | $2.15 | $7.12 |
| P/E Ratio | $50.86 | ★ N/A |
| Revenue Growth | N/A | ★ 45.38 |
| 52 Week Low | $34.88 | $6.00 |
| 52 Week High | $69.94 | $11.31 |
Technical Indicators
Market Signals| Indicator | DBD | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.06 | 59.91 |
| Support Level | $67.63 | $7.52 |
| Resistance Level | $69.94 | $7.77 |
| Average True Range (ATR) | 1.46 | 0.31 |
| MACD | -0.10 | 0.02 |
| Stochastic Oscillator | 46.51 | 83.85 |
Price Performance
Historical ComparisonAbout DBD Diebold Nixdorf Incorporated
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment. Geographically, the company generates maximum revenue from Europe, Middle East, and Africa (EMEA), followed by the Americas and the Asia-Pacific region.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.